Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ACADIA PHARMACEUTICALS INCACAD · Entity 3913 | Director · CEO | August 16, 2024 | August 20, 2024 |
| BELLICUM PHARMACEUTICALS, INCBLCM · Entity 107976 | Director | January 03, 2023 | January 05, 2023 |
| HERON THERAPEUTICS, INC. /DE/HRTX · Entity 7133 | Director | December 16, 2022 | December 20, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ACADIA PHARMACEUTICALS INC
Report date August 16, 2024 · Filed August 20, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 173,520 |
Reported balance
After 2024-08-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-08-16 · Grant · Acquired 17,333 · Balance 173,520 F1: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target. F2: Includes 956 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024. |
| Common StockSEC Table I · non-derivative | Direct | 218,302 |
Reported balance
After 2024-08-16 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2024-08-16 · Grant · Acquired 44,782 · Balance 218,302 F3: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target. |
| Common StockSEC Table I · non-derivative | Direct | 186,555 |
Reported balance
After 2024-08-19 transaction · row 3
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 3 · 2024-08-19 · Sale · Disposed 31,747 · Balance 186,555 F4: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.325, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target.
F2: Includes 956 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024.
F3: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target.
F4: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c).
F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.325, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
BELLICUM PHARMACEUTICALS, INC
Report date January 03, 2023 · Filed January 05, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 136,854 |
Reported balance
After 2023-01-03 transaction · row 1
1 source rowRow 1 · 2023-01-03 · Exercise / conversion · Acquired 74,739 · Balance 136,854 F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date.
HERON THERAPEUTICS, INC. /DE/
Report date December 16, 2022 · Filed December 20, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,032 |
Reported balance
After 2022-12-16 transaction · row 1
1 source rowRow 1 · 2022-12-16 · Grant · Acquired 38,580 · Balance 52,032 F1: The shares were granted as restricted stock units which vest in full on December 16, 2023. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.74 · Expires 2032-12-16 | Direct | 77,160 |
Reported balance
After 2022-12-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-12-16 · Grant · Acquired 77,160 · Balance 77,160 F2: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were granted as restricted stock units which vest in full on December 16, 2023.
F2: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 19, 2024 Filed Aug 20, 2024 22:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 31,747 | $15.28 | $485,094.16 |
DisclosureSEC source: 0001415889-24-021724 · form4-08202024_100838.xml · nonDerivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 186,555 F4 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.28 to $15.325, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantCommon Stock | 44,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021724 · form4-08202024_100838.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 218,302 F3 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on May 1, 2023 at 50% of target. Read SEC document |
| August 16, 2024 Filed Aug 20, 2024 22:40 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantCommon Stock | 17,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021724 · form4-08202024_100838.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,520 F1 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at incremental 25% of target. Together with the vesting on March 25, 2024, the performance stock units have vested at 75% of target. F2 · balance_after: Includes 956 shares acquired by the Reporting Person under the Issuer's Employee Stock Purchase Plan on May 15, 2024. Read SEC document |
| May 02, 2024 Filed May 3, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 11,427 | $16.94 | $193,573.38 |
DisclosureSEC source: 0001415889-24-012238 · form4-05032024_060513.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 155,231 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.94 to $17.015, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 22,391 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-012238 · form4-05032024_060513.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,173 Underlying: Common Stock · 22,391 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. Read SEC document |
| May 01, 2024 Filed May 3, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 22,391 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-012238 · form4-05032024_060513.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,658 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 08, 2024 Filed Apr 9, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 17,716 | $17.87 | $316,584.92 |
DisclosureSEC source: 0001415889-24-010604 · form4-04092024_060410.xml · nonDerivative · entry 4 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,267 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.77 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 08, 2024 Filed Apr 9, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 8,858 | $17.87 | $158,292.46 |
DisclosureSEC source: 0001415889-24-010604 · form4-04092024_060410.xml · nonDerivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,983 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.775 to $17.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 34,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010604 · form4-04092024_060410.xml · derivative · entry 6 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,666 Underlying: Common Stock · 34,666 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F6 · derivative.exercise_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from April 5, 2022 (the "grant date"); 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F6 · derivative.expiration_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from April 5, 2022 (the "grant date"); 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 17,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-010604 · form4-04092024_060410.xml · derivative · entry 5 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,667 Underlying: Common Stock · 17,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 34,666 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010604 · form4-04092024_060410.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 170,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| April 05, 2024 Filed Apr 9, 2024 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 17,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-010604 · form4-04092024_060410.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,175 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 27, 2024 Filed Mar 27, 2024 23:58 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 17,714 | $17.90 | $317,080.60 |
DisclosureSEC source: 0001415889-24-009271 · form4-03272024_110307.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,842 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of performance stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 23:58 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Option (Right to Buy) · Derivative | 286,451 | $0.00 Strike: $17.84 | $0.00 |
DisclosureSEC source: 0001415889-24-009271 · form4-03272024_110307.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 286,451 Underlying: Common Stock · 286,451 shares Expires 2034-03-24 F3 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on March 25, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 23:58 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantCommon Stock | 34,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-009271 · form4-03272024_110307.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,556 F1 · price: Represents acquisition of the Issuer's common stock upon vesting of the performance stock units granted to the Reporting Person on April 5, 2022 at 50% of target. Read SEC document |
| February 26, 2024 Filed Feb 27, 2024 23:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 5,577 | $24.67 | $137,584.59 |
DisclosureSEC source: 0001415889-24-005572 · form4-02272024_110210.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,890 F2 · kind: The mandatory sales reported in this Form 4 were made to cover withholding taxes and tax related items imposed by the Issuer in connection with the vesting of restricted stock units, and it is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 10,946 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005572 · form4-02272024_110210.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,946 Underlying: Common Stock · 10,946 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 23:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 10,946 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-24-005572 · form4-02272024_110210.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 08, 2024 Filed Jan 9, 2024 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,732 | $29.96 | $111,810.72 |
DisclosureSEC source: 0001209191-24-001269 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,521 F3 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.63 to $29.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 06, 2024 Filed Jan 9, 2024 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-001269 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,528 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F5 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F5 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2024 Filed Jan 9, 2024 23:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,528 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-24-001269 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · balance_after: Includes 1,594 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on May 15, 2023. On October 6, 2023, the Reporting Person filed a Form 4 which reported the same acquisition of shares in a footnote to Table I, Column 5, but inadvertently omitted such shares from the total in Table I, Column 5. The May 15, 2023 acquisition by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan is now correctly included in Table I, Column 5 of this Form 4. Read SEC document |
| October 06, 2023 Filed Oct 7, 2023 01:59 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 103,999 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-052389 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,332 Underlying: Common Stock · 103,999 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. F4 · derivative.expiration_date: Subject to accelerated vesting in certain circumstances, the restricted stock units vest as follows: 37.5% of the shares vest 18 months from the grant date; 12.5% of the shares vest on the second anniversary of the grant date; and 25% of the shares vest on each of the third and fourth anniversaries of the grant date. Read SEC document |
| October 06, 2023 Filed Oct 7, 2023 01:59 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 51,563 | $21.96 | $1,132,323.48 |
DisclosureSEC source: 0001209191-23-052389 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,131 F3 · price: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| October 05, 2023 Filed Oct 7, 2023 01:59 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 103,999 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-052389 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,694 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F2 · balance_after: Includes 1,594 shares acquired by the Reporting Person under the Issuer's 2004 Employee Stock Purchase Plan on May 15, 2023. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $20.77 | $0.00 |
DisclosureSEC source: 0001209191-23-042641 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 220,000 Underlying: Common Stock · 100,000 shares Expires 2024-07-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on July 15, 2015. The remaining shares vest and become exercisable thereafter in 36 equal monthly installments. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 100,000 | $30.04 | $3,004,350.00 |
DisclosureSEC source: 0001209191-23-042641 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,695 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.00 to $30.38, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 14, 2023 Filed Jul 18, 2023 22:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 100,000 | $20.77 | $2,077,000.00 |
DisclosureSEC source: 0001209191-23-042641 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 12, 2023 Filed Jul 14, 2023 00:27 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 55,104 | $25.05 | $1,380,448.88 |
DisclosureSEC source: 0001209191-23-042246 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,695 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.00 to $25.29, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| July 11, 2023 Filed Jul 14, 2023 00:27 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 16,498 | $25.00 | $412,450.00 |
DisclosureSEC source: 0001209191-23-042246 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,799 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023. Read SEC document |
| May 01, 2023 Filed May 2, 2023 23:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 7,806 | $21.18 | $165,331.08 |
DisclosureSEC source: 0001209191-23-026742 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,297 F1 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:16 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantRestricted Stock Units · Derivative | 89,564 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-027206 · doc4.xml · derivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,564 Underlying: Common Stock · 89,564 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning May 1, 2024. Read SEC document |
| May 01, 2023 Filed May 4, 2023 01:16 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | GrantStock Options (Right to Buy) · Derivative | 295,503 | $0.00 Strike: $21.75 | $0.00 |
DisclosureSEC source: 0001209191-23-027206 · doc4.xml · derivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,503 Underlying: Common Stock · 295,503 shares Expires 2033-05-01 F1 · derivative.exercise_date: 25% of the shares subject to the Stock Option will vest and become exercisable on May 1, 2024. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter. Read SEC document |
| April 29, 2023 Filed May 2, 2023 23:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026742 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,625 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 29, 2020. Read SEC document |
| April 29, 2023 Filed May 2, 2023 23:02 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 15,625 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-026742 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 06, 2023 Filed Apr 8, 2023 00:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 8,582 | $18.16 | $155,849.12 |
DisclosureSEC source: 0001209191-23-023862 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,478 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.1752, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| April 05, 2023 Filed Apr 8, 2023 00:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 17,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023862 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,000 Underlying: Common Stock · 17,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning April 5, 2023. Read SEC document |
| April 05, 2023 Filed Apr 8, 2023 00:34 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 17,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-023862 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,851 | $18.78 | $72,321.78 |
DisclosureSEC source: 0001209191-23-013472 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,727 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 10,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-013472 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,892 Underlying: Common Stock · 10,945 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning February 23, 2022. Read SEC document |
| February 23, 2023 Filed Feb 28, 2023 02:00 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 10,945 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-013472 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,578 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 01:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 3,904 | $17.13 | $66,876.69 |
DisclosureSEC source: 0001209191-23-002900 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,633 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.13 to $17.1939, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 01:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 9,528 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-002900 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,528 Underlying: Common Stock · 9,528 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 6, 2021. Read SEC document |
| January 06, 2023 Filed Jan 11, 2023 01:38 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 9,528 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-002900 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,537 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Acadia common stock. Read SEC document |
| January 03, 2023 Filed Jan 5, 2023 13:12 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 74,739 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-23-000421 · wf-form4_167294233628004.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,854 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on January 3, 2024, the one-year anniversary of the grant date. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:19 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantStock Option (Right to Buy) · Derivative | 77,160 | $0.00 Strike: $2.74 | $0.00 |
DisclosureSEC source: 0001209191-22-062184 · doc4.xml · derivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,160 Underlying: Common Stock · 77,160 shares Expires 2032-12-16 F2 · derivative.exercise_date: The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant. Read SEC document |
| December 16, 2022 Filed Dec 20, 2022 22:19 UTC | HERON THERAPEUTICS, INC. /DE/ HRTX · Entity 7133 | GrantCommon Stock | 38,580 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-062184 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,032 F1 · shares: The shares were granted as restricted stock units which vest in full on December 16, 2023. Read SEC document |
| October 15, 2022 Filed Oct 19, 2022 01:16 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionRestricted Stock Units · Derivative | 5,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-054026 · doc4.xml · derivative · entry 3 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,938 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning 10/15/19. Read SEC document |
| October 15, 2022 Filed Oct 19, 2022 01:16 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | SaleCommon Stock | 2,804 | $15.81 | $44,331.24 |
DisclosureSEC source: 0001209191-22-054026 · doc4.xml · nonDerivative · entry 2 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,009 F2 · kind: The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units. Read SEC document |
| October 15, 2022 Filed Oct 19, 2022 01:16 UTC | ACADIA PHARMACEUTICALS INC ACAD · Entity 3913 | Exercise / conversionCommon Stock | 5,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-054026 · doc4.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,813 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| September 01, 2022 Filed Sep 2, 2022 10:30 UTC | BELLICUM PHARMACEUTICALS, INC BLCM · Entity 107976 | Exercise / conversionCommon Stock | 43,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-22-024220 · wf-form4_166212900271886.xml · nonDerivative · entry 1 DAVIS STEPHEN · CIK 0001131146 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,115 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person was granted Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of BLCM common stock. The RSUs vest in full on September 1, 2023, the one-year anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.